Navigation Links
Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)

PRINCETON, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Novo Nordisk Inc. announced today that it has signed an exclusive agreement with Sciele Pharma, Inc. to market Prandin(R) (repaglinide). Under the terms of the agreement, Sciele will exclusively market Prandin(R) and, upon approval by the US Food and Drug Administration, PrandiMet(R) (the name submitted to FDA for a repaglinide/metformin fixed dose combination tablet) to physicians in the U.S., and will have a right of first refusal to obtain marketing rights in the U.S. to other Novo Nordisk products containing repaglinide, the active pharmaceutical ingredient in both Prandin(R) and PrandiMet(R).

"This partnership in the U.S. will enable us to increase the oral treatment options for people with type 2 diabetes to help them gain good glycemic control," said Martin Soeters, president of Novo Nordisk Inc. "It will also allow Novo Nordisk to concentrate on bringing our complete portfolio of three insulin analogs to health care providers, which provides the most viable opportunity to both help improve patient outcomes and realize our business aspirations, in the name of Changing Diabetes(R)."

Patrick Fourteau, president and CEO of Sciele Pharma, Inc., added, "We are pleased to initiate this partnership with Novo Nordisk, a company that is widely recognized as a global leader in diabetes care. Prandin(R) fits well within our Diabetes product portfolio and will be an excellent complement to Fortamet(R). Promoted by our Primary Care sales force, Prandin(R) will strengthen our presence in the diabetes treatment market."

About Prandin(R)

Prandin(R) is an oral blood glucose-lowering drug of the meglitinide class used in the management of type 2 diabetes mellitus. PrandiMet(R) is a combination tablet of repaglinide and metformin, which has yet to be approved by the FDA.

Prandin(R) is indicated as an adjunct to diet and exercise for patients with type 2 diabetes whose hyperglycemia cannot be controlled satisfactorily by diet and exercise alone. Prandin(R) is also indicated for combination therapy use (with metformin or thiazolidinediones) for patients whose hyperglycemia cannot be controlled by diet and exercise plus monotherapy with any of the following agents: metformin, sulfonylureas, repaglinide, or thiazolidinediones.

Prandin(R) is contraindicated in patients with diabetic ketoacidosis (with or without coma, type 1 diabetes, or known hypersensitivity to the drug or its inactive ingredients. Prandin(R) is not indicated for use in combination with NPH insulin. All oral blood glucose-lowering drugs, including Prandin(R), are capable of producing hypoglycemia. Full prescribing information is available at

Financial terms of the agreement are not being disclosed.

About Novo Nordisk Inc.

Novo Nordisk is a healthcare company with an 84-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 25,800 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit; for United States information, visit

About Sciele Pharma, Inc.

Sciele Pharma, Inc. is a pharmaceutical company specializing in sales, marketing and development of branded prescription products focused on Cardiovascular/Diabetes, Women's Heath and Pediatrics. The Company's Cardiovascular/Diabetes products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina and Type 2 diabetes; its Women's Health products are designed to improve the health and well-being of women and mothers and their babies; and its Pediatric products treat allergies, asthma, coughs and colds, and attention deficit and hyperactivity disorder (ADHD). Founded in 1992 and headquartered in Atlanta, Sciele Pharma employs more than 900 people. The Company's success is based upon placing the needs of patients first, improving health and quality of life, and implementing its business platform -- an Entrepreneurial Spirit, Innovation, Speed of Execution, Simplicity and Teamwork.

SOURCE Novo Nordisk Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
2. Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... SICM Module, an add-on scanning ion conductance microscopy module to Park NX10 that ... an AFM. , Park SICM benefits virtually all materials characterization that require measurements ...
(Date:12/1/2015)... SAN FRANCISCO , Dec. 1, 2015  Symic, ... and affect the extracellular matrix (ECM), today announced that ... financing to advance the company,s pipeline, including its lead ... Lilly Ventures and includes the participation by all existing ... new funding brings the total capital raised by Symic ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... global meeting this month and Dr. J. Kyle Mathews will join ... includes the new single site hysterectomy. , An experienced urogynecologist, founder of Plano ...
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem ... and aesthetics professionals from Central America and abroad for the first Iberoamerican Convention ... Panama Feb. 17-19, 2016. Testart will present and discuss new trends in anti-aging ...
Breaking Biology Technology:
(Date:11/17/2015)... 2015 Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" ... sale of broadly enabling, pressure cycling technology ("PCT")-based sample ... announced it has received gross proceeds of $745,000 from ... (the "Offering"), increasing the total amount raised to date ... closings are expected in the near future. ...
(Date:11/12/2015)... BOSTON , Nov. 12, 2015  A golden ... for Duchenne muscular dystrophy (DMD) has provided a new ... Boston Children,s Hospital, the Broad Institute of MIT and ... Brazil . Cell, ... some dogs "escape" the disease,s effects. The Boston Children,s ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing ... reliable analytical tools has been paving the way ... qualitative determination of discrete analytes in clinical, agricultural, ... are being predominantly used in medical applications, however, ... environmental sectors due to continuous emphasis on improving ...
Breaking Biology News(10 mins):